MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 A…
ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including…
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue…
COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives…
Oakville, Ontario--(Newsfile Corp. - February 29, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or…
FDA Clears Soldier Microcatheter for Localized Drug Delivery in Vascular InterventionsSUNNYVALE, Calif.--(BUSINESS WIRE)--Embolx Inc., a leading medical technology company developing…
STOCKHOLM, SWEDEN / ACCESSWIRE / February 29, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…
STOCKHOLM, SWEDEN / ACCESSWIRE / February 29, 2024 / PMD Device Solutions (STO:PROMO)(FRA:8T0) Press release: Stockholm, 29 February 2024. PMD…
GOTHENBURG, SWEDEN / ACCESSWIRE / February 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 29, 2024 - IRLAB Therapeutics…